Clinical Trial Update: A Comparative Study Of Iodine I 131 Tositumomab Therapeutic Regimen Versus Ibritumomab Tiuxetan Therapeutic Regimen [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing two radioimmunotherapy regimens (I-131 tositumomab vs ibritumomab tiuxetan) for follicular and other non-Hodgkin lymphomas was withdra…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma
• Follicular Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• Bexxar (tositumomab)
• Zevalin (ibritumomab tiuxetan)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Lymphoma, Small Cleaved-Cell, Follicular, Lymphoma, Large-Cell, Follicular | Phase 3 | Status: WITHDRAWN